![](/img/cover-not-exists.png)
Pharmacodynamic studies of the specific oral EGFR tyrosine kinase inhibitor (EGFR-TKI) zd1839 (‘Iressa’) in skin from cancer patients participating in phase I trials: histopathological and molecular consequences of receptor inhibition
J. Albanell, F. Rojo, S. Averbuch, A. Feyereislova, R. Herbst, P. LoRusso, D. Rischin, J. Gee, R. Nicholson, J. BaselgaVolume:
37
Year:
2001
Language:
english
DOI:
10.1016/s0959-8049(01)81071-6
File:
PDF, 177 KB
english, 2001